Oyster Point Pharma is a clinical-stage biopharmaceutical company that aims to develop and commercialize first-in-class pharmaceutical therapies for ocular surface diseases. The company's lead candidate, OC-01 nasal spray, has a unique mechanism of action in re-establishing tear film homeostasis by activating the trigeminal parasympathetic pathway to stimulate natural tear production. This nasal spray is specifically being developed to treat the signs and symptoms of dry eye disease. Oyster Point Pharma is focused on improving the quality of life for patients with ocular surface diseases and believes in the potential of its innovative therapies to do so.
Oyster Point Pharma Inc's ticker is OYST
The company's shares trade on the NASDAQ stock exchange
They are based in Princeton, New Jersey
There are 11-50 employees working at Oyster Point Pharma Inc
It is oysterpointrx.com
Oyster Point Pharma Inc is in the Healthcare sector
Oyster Point Pharma Inc is in the Biotechnology industry
The following five companies are Oyster Point Pharma Inc's industry peers: